The portfolio maintains a sizable cost advantage over competitors, priced within the lowest fee quintile among peers.
VanEck Biotech ETF BBH
- NAV / 1-Day Return 154.66 / −1.80 %
- Total Assets 424.7 Mil
-
Adj. Expense Ratio
- Expense Ratio 0.350%
- Distribution Fee Level —
- Share Class Type —
- Category Health
- Investment Style Mid Blend
- Min. Initial Investment —
- Status Open
- TTM Yield 0.43%
- Turnover 18%
USD | NAV as of Apr 26, 2024 | 1-Day Return as of Apr 26, 2024, 1:01 AM GMT+0
Morningstar’s Analysis BBH
Will BBH outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 68.1
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Amgen Inc | 15.08 | 63.9 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 9.64 | 40.9 Mil | Healthcare |
Gilead Sciences Inc | 7.81 | 33.1 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 7.72 | 32.7 Mil | Healthcare |
Moderna Inc | 5.74 | 24.3 Mil | Healthcare |
IQVIA Holdings Inc | 4.93 | 20.9 Mil | Healthcare |
argenx SE ADR | 4.45 | 18.9 Mil | Healthcare |
Icon PLC | 4.29 | 18.2 Mil | Healthcare |
Illumina Inc | 4.28 | 18.1 Mil | Healthcare |
Biogen Inc | 4.17 | 17.7 Mil | Healthcare |